UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2563-2574

2016

Volltextzugriff (PDF)

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

British journal of cancer, 2021-01, Vol.124 (2), p.383-390

2021

Volltextzugriff (PDF)

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Clinical cancer research, 2007-03, Vol.13 (5), p.1576-1583

2007

Volltextzugriff (PDF)

Discovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

Journal of medicinal chemistry, 2021-11, Vol.64 (21), p.16213-16241

2021

Volltextzugriff (PDF)

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Clinical cancer research, 2017-02, Vol.23 (4), p.1025-1035

2017

Volltextzugriff (PDF)

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

Oncogene, 2003-08, Vol.22 (32), p.4953-4963

2003

Volltextzugriff (PDF)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

HemaSphere, 2023-08, Vol.7 (S3), p.e68516d0-n/a

2023

Volltextzugriff (PDF)

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

Current topics in medicinal chemistry, 2005-01, Vol.5 (2), p.215-229

2005

Volltextzugriff (PDF)

A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling

Proceedings of the National Academy of Sciences - PNAS, 2000-08, Vol.97 (16), p.8991-8996

2000

Volltextzugriff (PDF)

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

Journal of medicinal chemistry, 2006-01, Vol.49 (2), p.441-444

2006

Volltextzugriff (PDF)

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Blood, 2018-11, Vol.132 (Supplement 1), p.3505-3505

2018

Volltextzugriff (PDF)

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.6075-6075

2023

Volltextzugriff (PDF)

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2024-06, Vol.331 (21), p.1814

2024

Volltextzugriff (PDF)

Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S161-S161

2024

Volltextzugriff (PDF)

ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S270-S271

2024

Volltextzugriff (PDF)

Abstract 5184: Biomarker results from PEVENAZA, a randomized phase 2 study of venetoclax and azacitidine +/- pevonedistat in newly diagnosed AML patients unfit for intensive chemotherapy: Increased efficacy in a subset of patients with IDH1/2 mutations and other observations

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5184-5184

2024

Volltextzugriff (PDF)

Oral Abstract: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S145-S145

2023

Volltextzugriff (PDF)

ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S245-S245

2023

Volltextzugriff (PDF)

POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S154-S154

2023

Volltextzugriff (PDF)

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3047-3047

2015

Volltextzugriff (PDF)

Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

Cancer immunology research, 2020-03, Vol.8 (3_Supplement), p.B55-B55

2020

Volltextzugriff (PDF)

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (∗)

The Journal of biological chemistry, 1996-02, Vol.271 (6), p.2921-2928

1996

Volltextzugriff (PDF)

Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1677-1677

2014

Volltextzugriff (PDF)

Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor

Diabetes (New York, N.Y.), 1994-11, Vol.43 (11), p.1297-1303

1994

Volltextzugriff (PDF)

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2515-2515

2010

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(40)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(17)
Animals
(9)
Covid-19
(5)
Mice
(5)
Oncology
(5)
Pediatrics
(5)
Severe Acute Respiratory Syndrome Coronavirus 2
(5)
Biochemistry & Molecular Biology
(4)
Cancer
(4)
Cell Line
(4)
Chemistry, Medicinal
(4)
Child
(4)
Coronaviruses
(4)
Infections
(4)
Patients
(4)
Pharmacology & Pharmacy
(4)
Sars-Cov-2
(4)
Xenograft Model Antitumor Assays
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Discovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling

Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy

ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Abstract 5184: Biomarker results from PEVENAZA, a randomized phase 2 study of venetoclax and azacitidine +/- pevonedistat in newly diagnosed AML patients unfit for intensive chemotherapy: Increased efficacy in a subset of patients with IDH1/2 mutations and other observations

Oral Abstract: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC)

Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (∗)

Abstract 1677: Preclinical activity of Vintafolide/MK-8109 monotherapy and in combination with standard of care therapy in triple-negative breast cancer models

Insulin receptor signaling in Madin-Darby canine kidney cells overexpressing the human insulin receptor

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

Suchergebnisse filtern